Western Wealth Management LLC Purchases 2,115 Shares of Stryker Corporation $SYK

Western Wealth Management LLC lifted its position in shares of Stryker Corporation (NYSE:SYK) by 33.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,493 shares of the medical technology company’s stock after buying an additional 2,115 shares during the period. Western Wealth Management LLC’s holdings in Stryker were worth $2,791,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new stake in shares of Stryker in the 2nd quarter valued at $205,000. Marshall Wace LLP grew its holdings in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new position in shares of Stryker during the 2nd quarter valued at $219,000. Finally, HUB Investment Partners LLC purchased a new position in Stryker in the 2nd quarter worth $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $326.41 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market cap of $125.13 billion, a PE ratio of 33.82, a P/E/G ratio of 2.23 and a beta of 0.77. The business has a 50 day moving average of $317.28 and a 200 day moving average of $334.92. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $401.99.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 24.06% and a net margin of 14.43%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insider Transactions at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 323,264 shares of company stock valued at $100,659,489. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. BMO Capital Markets assumed coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target for the company. Barclays reduced their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Wells Fargo & Company decreased their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Needham & Company LLC lowered their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, Evercore set a $350.00 target price on Stryker in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $387.88.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter revenue of $6.59 billion, up 9.4% year over year, while adjusted EPS of $3.69 exceeded consensus estimates. Organic sales growth reached 9%, supported by strong demand for orthopedic, spinal and other medical devices. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Management said it has regained momentum following the cyber disruption and resumed share repurchases. Its full-year guidance calls for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. Stryker expects 2026 organic sales growth and adjusted EPS
• Positive Sentiment: JPMorgan maintained an “overweight” rating, although it reduced its price target to $350. Truist raised its target to $340 while retaining a “hold” rating, and BTIG continues to rate the shares “buy.”
• Neutral Sentiment: The updated guidance was narrower but remained broadly close to prior expectations and analyst forecasts. This suggests operational stability, but not a major upside revision that could drive a stronger investor reaction.
• Neutral Sentiment: Analyst opinion remains generally constructive, with no recent sell ratings cited and a six-month median price target of $385, though target reductions indicate some caution regarding valuation or near-term upside.
• Negative Sentiment: The main pressure on SYK appears to be an expectations reset: despite the earnings beat, investors had anticipated a more substantial increase to full-year guidance after the cyberattack recovery. SYK falls despite Q2 earnings beat
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no purchases and substantial sales over the past six months. This may add to investor concerns about valuation and management confidence, although the trades do not necessarily reflect current operating performance.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.